In cell‐based in vitro assays, PE0116 triggers NF‐κB signal pathway activation, enhances T‐cell activation, and promotes dose‐dependent secretion of anti‐tumor cytokines in response to suboptimal CD3‐TCR signal, showing mighty agonistic efficiency, which was slightly inferior to Urelumab and much superior to Utomilumab in the presence of cross‐linking. Here, NFKB1 is linked to neoplasm.